Shortly thereafter, the genomic landscape of glioma was described based on large cohorts of patients (Cancer Genome Atlas Research Network, 2008), facilitating the identification of key genetic and epigenetic alterations, e.g., mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the glioma-CpG island methylator phenotype (g-CIMP), which are associated with a relatively favorable prognosis (Yan et al, 2009; Noushmehr et al, 2010). The gene discussed is IDH2; the disease is central nervous system cancer.